-
EU Data Watchdog Slaps €746M Penalty On Amazon
Friday, July 30, 2021 - 11:29am | 304Read More...On July 16, the Luxembourg National Commission for Data Protection (the CNPD) held Amazon.com Inc's (NASDAQ: AMZN) Amazon Europe Core S.à r.l. for not complying with the personal data processing under the EU General Data Protection Regulation. It levied a...
-
Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer
Friday, July 30, 2021 - 9:05am | 195Read More...The European Commission (EC) has approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer. The approval covers patients who have residual pathologic disease...
-
Merck's Keytruda-Chemo Combo Wins European Approval In Esophagus Cancer
Tuesday, June 29, 2021 - 9:20am | 165Read More...The European Commission has approved Merck & Co Inc's (NYSE: MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment of Esophageal Carcinoma or Gastroesophageal Junction (GEJ) Adenocarcinoma. The approval covers patients...
-
Google Relaxes Search Engine Dominance Practices On European Android
Wednesday, June 9, 2021 - 12:12pm | 442Read More...Alphabet Inc's (NASDAQ: GOOG) (NASDAQ: GOOGL) Google will permit free competition for default search engines on the European Android devices effective September, succumbing to an EU antitrust commitment made two years ago, the company said in a blog. Google incorporated some final...
-
European Commission Clarifies Revised Copyright Rules Following Criticism: Reuters
Friday, June 4, 2021 - 12:35pm | 330Read More...The European Commission sought to clarify the scope and liability of 2020 revised copyright rules to resolve criticism from France, Poland, E.U. broadcasters, and internet activists, Reuters reports. The revised rules aimed to fairly compensate the bloc's $1 trillion creative industry and...
-
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer
Friday, May 28, 2021 - 8:27am | 202Read More...AstraZeneca Plc’s (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed...
-
European Competition Watchdog Launches Antitrust Scrutiny in Facebook's Online Marketplace: FT
Wednesday, May 26, 2021 - 2:02pm | 268Read More...The European Competition Commissioner Margrethe Vestager is set to launch an antitrust probe against Facebook Inc (NASDAQ: FB) for alleged unfair dominance by its online Marketplace, the Financial Times reports. The EU officials have sent a minimum of three rounds of questions to...
-
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia
Tuesday, May 25, 2021 - 11:28am | 214Read More...The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). Venclyxto is approved in combination with a hypomethylating agent, azacitidine or decitabine, in AML...
-
European Commission Inks Third Supply Pact With BioNTech-Pfizer For 1.8B Vaccine Doses
Thursday, May 20, 2021 - 6:22am | 234Read More...The European Commission has signed a third contract with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) for an additional 1.8 billion doses of its COVID-19 vaccine, Comirnaty. The contract reserves the doses on behalf of all European Union member states,...
-
AstraZeneca Can Face Legal Action Over Vaccine Shortfalls To EU: Reuters
Thursday, April 22, 2021 - 6:07am | 486Read More...The European Commission is reportedly working on legal proceedings against AstraZeneca Plc (NASDAQ: AZN) as the company cut COVID-19 vaccine deliveries to the European Union. The move comes as one step further as an E.U. plan to break off ties with AstraZeneca after...
-
Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl
Tuesday, March 30, 2021 - 7:16am | 221Read More...The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The approval covers reducing the risk of cardiovascular events in high-risk,...
-
PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy
Tuesday, March 30, 2021 - 7:05am | 200Read More...The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two months and older. Evrysdi will be for SMA Type 1, Type 2, or Type 3 patients...
-
Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis
Tuesday, March 30, 2021 - 7:03am | 207Read More...Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license...
-
Incyte's Pemazyre Wins European Approval For Bile Duct Cancer
Monday, March 29, 2021 - 2:34pm | 254Read More...The European Commission (EC) has approved Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, rare cancer that forms in the bile duct. The approval covers adults' treatment with locally advanced or metastatic cholangiocarcinoma with a...
-
Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer
Monday, March 29, 2021 - 2:27pm | 249Read More...The European Commission has granted conditional marketing authorization for Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Nexpovio (selinexor) for multiple myeloma. The approval covers Nexpovio combined with dexamethasone for multiple myeloma in adult patients who have...
